CRANBURY, N.J.--(BUSINESS WIRE)--Aug. 16, 2006--Kos Pharmaceuticals, Inc. (Nasdaq:KOSP) today announced that the Company intends to request a hearing before a Nasdaq Listing Qualifications Panel (the “Panel”) in response to the receipt of a Nasdaq Staff Determination letter dated August 14, 2006, indicating that the Company is not in compliance with the filing requirements for continued listing as set forth in Marketplace Rule 4310(c)(14). The letter was issued by the Nasdaq Listing Qualifications staff due to the delayed filing of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2006. The Company’s shares will remain listed on the Nasdaq Stock Market pending a decision by the Panel.
